Selecting the right preclinical species for screening oral dosage form for PK studies

Learn how Syngene helped a pharma client optimize extended-release drug development by identifying the right animal species as a preclinical model. This decision enhanced PK study accuracy, reduced development time, and supported regulatory success for a once-daily epilepsy treatment.

Author

Latest Blogs

Tirbanibulin and targeted dermal delivery in topical drug development

Therapeutics 2.0: Veterinary Oncology and Peptide Conjugates for Companion Animal Health

Current Toxicology Developments: Advancing Digital Pathology in Predictive, Mechanistic, and Human-Relevant Safety Science

GXP compliance balancing speed and quality in outsourced R&D

Speed vs. quality: balancing timelines in outsourced R&D with GXP compliance

Reimagining CROs: Integrated Innovation Partnerships as the Future of Drug Discovery

HPAPI containment facility supporting supply chain resilience

Improving Supply Chain Resilience: HPAPI Containment And Batch Reliability In Global Pharma Manufacturing

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details